說明
HSCT是治療多種血液系統惡性腫瘤和非惡性疾病的公認療法,但它也伴隨著嚴重的副作用。
CliniMACS®細胞分離系統提供了多種工具,能夠從造血幹細胞移植物中去除T細胞,T細胞亞群,B細胞和其他不需要的細胞,從而克服了復發和諸如移植物抗宿主病的副作用。
基於Miltenyi Biotec的細胞分離技術和針對不同表位的臨床級抗體,正在評估不同的臨床策略來設計用於不同目的的干細胞移植物。
進一步資訊請與我們聯繫。
Description
While HSCT is a well-founded therapeutic option for the treatment of a variety of hematologic malignancies and non-malignant diseases, it is also associated with severe side effects. The CliniMACS® Cell Separation System offers a variety of tools that enables the removal of T cells, T cells subsets, B cells, and other unwanted cells from hematopoietic stem cell grafts to overcome relapse and side effects like graft-versus-host disease. Different clinical strategies are being evaluated to engineer stem cell grafts for different purposes based on Miltenyi Biotec's cell separation technologies and clinical grade antibodies for different epitopes.